Biologics Contract Development Market Size & Share, By Source (Mammalian, Microbial), Service Type, Indication (Oncology, Immunological Disorders), Regional Forecast, Industry Players, Growth Statistics Report 2024-2032

Market Outlook:

Biologics Contract Development Market was over USD 8.08 Billion in 2023 and is expected to exceed USD 16.42 Billion by end of the year 2032, observing around 8.2% CAGR between 2024 and 2032.

• Base Year Value (2023): USD 8.08 Billion
• CAGR (2024-2032): 8.2%
• Forecast Year Value (2032): USD 16.42 Billion
• Historical Data Period: 2019-2023
• Largest Region: North America
• Forecast Period: 2024-2032

Market Dynamics:

Growth Drivers & Opportunity:

Biologics contract development market is expected to witness significant growth due to increasing demand for personalized medicine, advancements in biotechnology, and rising investments in research and development.

Report Scope

Report Coverage	Details
Segments Covered	Source, Service, Indication
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	WuXi Biologics, Abzena, Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific, Curia Global,, Genscript, Bionova Scientific,, BioXcellence, STC Biologics

Industry Restraints:

However, the market may face challenges such as stringent regulatory requirements and high costs associated with biologics development and manufacturing.

Growth Drivers & Opportunity:

Furthermore, the growing prevalence of chronic diseases and increasing adoption of biologics for the treatment of various diseases are expected to drive the growth of the market in the coming years.

Report Scope

Report Coverage	Details
Segments Covered	Source, Service, Indication
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	WuXi Biologics, Abzena, Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific, Curia Global,, Genscript, Bionova Scientific,, BioXcellence, STC Biologics

Industry Restraints:

The complex manufacturing processes and the need for specialized expertise may act as restraints for the biologics contract development market.

Regional Forecast:

North America:

The Biologics Contract Development market in North America is dominated by the United States, which is one of the largest markets globally. The presence of key players, significant investments in research and development, and favorable government regulations contribute to the growth of the market in the region. Canada also plays a significant role in the North American market, with a growing number of contract development organizations offering biologics services.

Asia Pacific:

In Asia Pacific, China is a key player in the Biologics Contract Development market, with a rapidly expanding biopharmaceutical industry and increasing outsourcing activities. Japan and South Korea also contribute significantly to the market, with advanced infrastructure and technological capabilities supporting the growth of biologics contract development services in the region.

Europe:

Europe is a prominent market for Biologics Contract Development, with countries like the United Kingdom, Germany, and France leading the way. The presence of established contract development organizations, strong regulatory framework, and increasing demand for biologics services drive the growth of the market in Europe. The United Kingdom, in particular, is known for its expertise in biologics development, making it a key player in the European market.

Segmentation Analysis:

In terms of segmentation, the global Biologics Contract Development market is analyzed on the basis of Source, Service, Indication.

Mammalian Source:

The biologics contract development market for mammalian source is anticipated to witness significant growth due to the increasing demand for mammalian cell line-based biologics production. Mammalian cells offer several advantages such as high productivity, proper post-translational modifications, and ability to produce complex proteins. These factors are driving the market growth for mammalian source biologics contract development services.

Microbial Source:

The microbial source segment in the biologics contract development market is also expected to show substantial growth. Microbial expression systems, such as bacteria and yeast, are widely used for the production of recombinant proteins. These systems are cost-effective and can produce high yields of proteins in a short period of time. The microbial source segment is likely to experience growth due to the rising demand for microbial-based biologics development services.

Service Type:

The service type segment in the biologics contract development market includes cell line development, process development, analytical services, and others. Cell line development services are crucial for the production of biologics as they involve the selection and generation of stable cell lines for protein expression. Process development services focus on optimizing the bioprocess to enhance productivity and efficiency. Analytical services play a key role in ensuring the quality, safety, and efficacy of biologics. The demand for these services is expected to drive growth in the biologics contract development market.

Indication Oncology:

The oncology indication segment in the biologics contract development market is witnessing significant growth due to the increasing prevalence of cancer worldwide. Biologics play a crucial role in the treatment of various types of cancer by targeting specific molecules involved in cancer growth and progression. The development of biologics for oncology indications requires specialized expertise and services, driving the demand for biologics contract development in this segment.

Indication Immunological Disorders:

The immunological disorders indication segment in the biologics contract development market is also expected to show growth. Biologics are widely used in the treatment of various immunological disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The development of biologics for immunological disorders involves complex processes and specialized services, creating opportunities for growth in this segment of the biologics contract development market.

Competitive Landscape:

Top Market Players:

Lonza Group

Boehringer Ingelheim GmbH

Samsung Biologics

WuXi Biologics

Catalent, Inc.

Thermo Fisher Scientific Inc.

Charles River Laboratories International, Inc.

Patheon N.V.

Toxikon Corporation

Evotec AG

The competitive landscape in the Biologics Contract Development Market is fierce and rapidly evolving with numerous companies vying for market share. These companies offer a range of services including cell line development, process development, analytical testing, and manufacturing of biologics for pharmaceutical and biotechnology companies globally. The market is characterized by intense competition, technological advancements, strategic collaborations, and acquisitions to strengthen their market position and expand their service offerings to meet the growing demand for biologics contract development services.